223 related articles for article (PubMed ID: 21878447)
1. Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials.
Schroen AT; Petroni GR; Wang H; Thielen MJ; Sargent D; Benedetti JK; Cronin WM; Wickerham DL; Wang XF; Gray R; Cohn WF; Slingluff CL; Djulbegovic B
Clin Trials; 2011 Oct; 8(5):591-600. PubMed ID: 21878447
[TBL] [Abstract][Full Text] [Related]
2. Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups.
Schroen AT; Petroni GR; Wang H; Thielen MJ; Gray R; Benedetti J; Wang XF; Sargent DJ; Wickerham DL; Cronin W; Djulbegovic B; Slingluff CL
Clin Cancer Res; 2012 Jan; 18(1):256-62. PubMed ID: 21976533
[TBL] [Abstract][Full Text] [Related]
3. Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials.
Schroen AT; Petroni GR; Wang H; Gray R; Wang XF; Cronin W; Sargent DJ; Benedetti J; Wickerham DL; Djulbegovic B; Slingluff CL
Clin Trials; 2010 Aug; 7(4):312-21. PubMed ID: 20595245
[TBL] [Abstract][Full Text] [Related]
4. Accrual experience of National Cancer Institute Cooperative Group phase III trials activated from 2000 to 2007.
Korn EL; Freidlin B; Mooney M; Abrams JS
J Clin Oncol; 2010 Dec; 28(35):5197-201. PubMed ID: 21060029
[TBL] [Abstract][Full Text] [Related]
5. Accrual to National Cancer Institute-sponsored non-small-cell lung cancer trials: insights and contributions from the CCOP program.
Lyss AP; Lilenbaum RC
Clin Lung Cancer; 2009 Nov; 10(6):410-3. PubMed ID: 19900858
[TBL] [Abstract][Full Text] [Related]
6. Predicting Low Accrual in the National Cancer Institute's Cooperative Group Clinical Trials.
Bennette CS; Ramsey SD; McDermott CL; Carlson JJ; Basu A; Veenstra DL
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26714555
[TBL] [Abstract][Full Text] [Related]
7. Phase III clinical trial development: a process of chutes and ladders.
Dilts DM; Cheng SK; Crites JS; Sandler AB; Doroshow JH
Clin Cancer Res; 2010 Nov; 16(22):5381-9. PubMed ID: 21062928
[TBL] [Abstract][Full Text] [Related]
8. A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies.
Cheng SK; Dietrich MS; Dilts DM
Clin Cancer Res; 2010 Nov; 16(22):5557-63. PubMed ID: 21062929
[TBL] [Abstract][Full Text] [Related]
9. Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement.
Tang C; Sherman SI; Price M; Weng J; Davis SE; Hong DS; Yao JC; Buzdar A; Wilding G; Lee JJ
Clin Cancer Res; 2017 Mar; 23(6):1414-1421. PubMed ID: 28275168
[No Abstract] [Full Text] [Related]
10. Predicting accrual achievement: monitoring accrual milestones of NCI-CTEP-sponsored clinical trials.
Cheng SK; Dietrich MS; Dilts DM
Clin Cancer Res; 2011 Apr; 17(7):1947-55. PubMed ID: 21447723
[TBL] [Abstract][Full Text] [Related]
11. Challenges Facing Early Phase Trials Sponsored by the National Cancer Institute: An Analysis of Corrective Action Plans to Improve Accrual.
Massett HA; Mishkin G; Rubinstein L; Ivy SP; Denicoff A; Godwin E; DiPiazza K; Bolognese J; Zwiebel JA; Abrams JS
Clin Cancer Res; 2016 Nov; 22(22):5408-5416. PubMed ID: 27401246
[TBL] [Abstract][Full Text] [Related]
12. Enrolling Older Adults Onto National Cancer Institute-Funded Clinical Trials in Community Oncology Clinics: Barriers and Solutions.
Hopkins JO; Braun-Inglis C; Guidice S; Wells M; Moorthi K; Berenberg J; St Germain D; Mohile S; Hudson MF
J Natl Cancer Inst Monogr; 2022 Dec; 2022(60):117-124. PubMed ID: 36519815
[TBL] [Abstract][Full Text] [Related]
13. The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations.
Denicoff AM; McCaskill-Stevens W; Grubbs SS; Bruinooge SS; Comis RL; Devine P; Dilts DM; Duff ME; Ford JG; Joffe S; Schapira L; Weinfurt KP; Michaels M; Raghavan D; Richmond ES; Zon R; Albrecht TL; Bookman MA; Dowlati A; Enos RA; Fouad MN; Good M; Hicks WJ; Loehrer PJ; Lyss AP; Wolff SN; Wujcik DM; Meropol NJ
J Oncol Pract; 2013 Nov; 9(6):267-76. PubMed ID: 24130252
[TBL] [Abstract][Full Text] [Related]
14. Unsuccessful trial accrual and human subjects protections: an empirical analysis of recently closed trials.
Carlisle B; Kimmelman J; Ramsay T; MacKinnon N
Clin Trials; 2015 Feb; 12(1):77-83. PubMed ID: 25475878
[TBL] [Abstract][Full Text] [Related]
15. Leveraging National Cancer Institute Programmatic Collaboration for Uterine Cervix Cancer Patient Accrual in Puerto Rico.
Kunos CA; Massett HA; Galassi A; Walker JL; Good MJ; Díaz LB; McCaskill-Stevens W
Front Oncol; 2018; 8():102. PubMed ID: 29692980
[TBL] [Abstract][Full Text] [Related]
16. Sustainability and performance of the National Cancer Institute's Community Clinical Oncology Program.
Carpenter WR; Fortune-Greeley AK; Zullig LL; Lee SY; Weiner BJ
Contemp Clin Trials; 2012 Jan; 33(1):46-54. PubMed ID: 21986391
[TBL] [Abstract][Full Text] [Related]
17. Who's Eligible Anyway? Risk Modeling for Clinical Trial Accrual.
Mileham KF; Kim ES
Clin Cancer Res; 2016 Nov; 22(22):5397-5399. PubMed ID: 27601589
[TBL] [Abstract][Full Text] [Related]
18. Reimbursement Matters: Overcoming Barriers to Clinical Trial Accrual.
Lee SJC; Murphy CC; Gerber DE; Geiger AM; Halm E; Nair RG; Cox JV; Tiro JA; Skinner CS
Med Care; 2021 May; 59(5):461-466. PubMed ID: 33492049
[TBL] [Abstract][Full Text] [Related]
19. Speed of Accrual Into Phase III Oncology Trials: A Comparison Across Geographic Locations.
Ruther NR; Mathiason MA; Wee SK; Emmel AE; Go RS
Am J Clin Oncol; 2015 Dec; 38(6):575-82. PubMed ID: 24517955
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Maryland cancer patient participation in national cancer institute-supported cancer treatment clinical trials.
Baquet CR; Ellison GL; Mishra SI
J Clin Oncol; 2008 Jul; 26(20):3380-6. PubMed ID: 18612153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
